TABLE 1.
Most used GLP1-receptor agonists: Descriptions of the different GLP-1 receptor agonists
| Generic name | Active component | Administration | Half-time | Approved indications |
|---|---|---|---|---|
| GLP-1 receptor agonists | ||||
| Exenatide | GLP-1 | SC | 2.4 h | T2DM |
| Lixisenatide | GLP-1 | SC | 3 h | T2DM |
| Liraglutide | GLP-1 | SC | 13 h | T2DM Obesity |
| Semaglutide | GLP-1 | SC + PO | 1 wk | T2DM Obesity |
| Dulaglutide | GLP-1 | SC | 5 d | T2DM |
| Dual agonists | ||||
| Tirzepatide | GLP-1 and glucose-dependent insulinotropic polypeptide | SC | 5 d | T2DM Obesity |
| Survodutide | GLP-1 and glucagon | SC | 6 d | Not yet approved |
| Efinopegdutide | GLP-1 and glucagon | SC | 8 d | Not yet approved |
Abbreviations: PO, per oral; T2DM, type 2 diabetes mellitus.